To develop a statistical model that predicts the histology (necrosis, mature teratoma, or cancer) after chemotherapy for metastatic nonseminomatous germ cell tumor (NSGCT).
sis/fibrosis, mature teratoma, or cancer. Because these three histologies are not considered to have a similar necessity of resection, attempts have been made to predict the postchemotherapy histology. 3 " For patients with a very high likelihood of necrosis, the risk of leaving mature teratoma or cancer unresected might not be balanced by the disadvantages of resection (morbidity, mortality, financial costs).
The decision to perform surgical resection is especially difficult in patients with small residual masses. In some centers, resection is performed if the residual mass exceeds an arbitrarily chosen size (eg, 20 mm 6 or 10 mm 7 "8), with the argument that the probability of cancer or mature teratoma is very low in smaller masses. When no pathologic mass can be detected on the postchemotherapy computed tomography (CT) scan, some surgeons still advocate resection in the following situations: if a teratomatous component is present in the primary tumors; if a prechemotherapy abdominal lymph node metastasis is greater than 30 mm 3 ; or if resection is performed as a principle in all patients.'" The fraction of resected patients varies from approximately 25% (masses > 20 mm 6 ) to 86% in accordance with the selection criteria." 1 The extent of surgery is debatable; some surgeons excise only visible mass during chemotherapy. Multivariate combination of predictors yielded reliable models (goodness-of-fit tests, P > .20), which discriminated necrosis well from other histologies (area under the receiver operating characteristic (ROC) curve, .84), but which discriminated cancer only reasonably from mature teratoma (area, .66). Internal and external validation confirmed these findings.
Conclusion:
The validated models estimate with high accuracy the histology at resection, especially necrosis, based on well-known and readily available predictors. The predicted probabilities may help to choose between immediate resection of a residual mass or follow-up, taking into account the expected benefits and risks of resection, feasibility of frequent follow-up, the financial costs, and the patient's individual preferences.
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abnormal masses, 6 whereas others perform a more extensive retroperitoneal lymph node dissection." In addition to the size of the residual mass, other characteristics may be considered in the decision to resect a residual mass. Previously recognized predictors of necrosis include the absence of teratoma elements in the primary tumor, prechemotherapy tumor marker levels (alfa-fetoprotein [AFP] , human chorionic gonadotropin, [HCG] , and lactate dehydrogenase [LDH] ), prechemotherapy and postchemotherapy mass size, and shrinkage STEYERBERG ET AL our aim is to estimate the probabilities of necrosis, mature teratoma, and cancer in residual retroperitoneal masses based on these well-known and readily available predictors. To obtain a sufficiently large number of patients for statistical analyses, we collected an international data set comprising data from six study groups.
PATIENTS AND METHODS

Inclusion Criteria
The international data set consisted of patients with metastatic nonseminomatous testicular cancer, including patients with pure seminoma and elevated prechemotherapy tumor marker levels, who underwent resection of retroperitoneal residual masses after cisplatin-based induction chemotherapy. Patients with elevated levels of tumor markers AFP or HCG at the time of surgery, with extragonadal tumors, with pure seminoma (normal prechemotherapy AFP and HCG), and those who underwent resection after relapse of tumor after initial chemotherapy were excluded.
Study Descriptions
Individual patient data were retrieved according to a data form that included basic patient identification, year and type of treatment, histology, and information on the following predictors: presence of teratoma elements in the primary tumor, prechemotherapy tumor marker levels (AFP, HCG, LDH), and prechemotherapy and postchemotherapy mass size. Consistency of the data was checked with the participants (agreement with published figures and completion of missing values as far as possible). The studies are numbered I to 6 (Table 1) and are briefly described here; details of treatment and resection policy can be found in the original publications. Study no. 1V included 122 patients, all of whom fulfilled the inclusion criteria. Study no. 25,13,14 included 149 patients, 22 of whom were excluded (11 with extragonadal tumors, 10 with elevated postchemotherapy marker levels (AFP/HCG), and one with both characteristics 
Definitions of Predictors and Histology
The primary tumor histology was defined as teratoma-positive or teratoma-negative, 34 The histology of the resected material was classified as cancer, mature teratoma, or necrosis according to the worst histologic element. Thus, mature teratoma referred to masses that contained mature teratoma and possibly also necrosis/fibrosis, but no viable cancer cells, and cancer referred to masses that contained viable cancer cells and possibly mature teratoma and/or necrosis.
Missing Values
Of the 556 patients who were included in the analysis, 429 had complete values for all predictors. Missing values were filled in (or imputed) for 115 patients who were missing one value, and the 12 patients with two or more missing values were excluded. Imputation was based on the correlation between each variable with missing values and the other predictors. 23 The correlation was estimated from the 429 complete cases.
The missing values are filled in (or imputed) assuming their absence is random. Regression models for the variables with missing values were estimated from the complete cases. Multiple linear regression models were estimated for the continuous predictors mass size (on the prechemotherapy or postchemotherapy CT scan) and prechemotherapy marker values (AFP, HCG, and LDHt,). All continuous predictors had skewed distributions, which became more normally distributed by log-transformation. Independent variables were selected in a stepwise manner, with P < .05 for entry of variables and P < .10 for removal of variables (SPSS/PC+ software; SPSS Inc, Chicago, IL). A logistic regression model was used to estimate the presence of teratoma elements in the primary tumor. The correlation matrix between the predictors is shown in Table 2 . It appears that strong correlations exist between several predictors, and thus imputation based on the values of the other predictors is attractive. Table 3 shows the independent variables used to impute the missing values as estimated from the complete cases. Missing values were imputed in 115 cases. For the patient with missing primary histology, the predicted probability was .20, and hence the value 0 was imputed PREDICTION OF RESIDUAL MASS HISTOLOGY The results of this analysis were compared with the results obtained when complete cases only were considered.
Statistical Analysis
The histology at resection (necrosis, mature teratoma, or cancer) was predicted using two statistical models. The first model estimated the probability of necrosis by comparing patients with necrosis at resection with patients showing other histologies (teratoma or cancer). The second model aimed to distinguish between cancer and teratoma in the patients who did not have necrosis at resection. This second analysis estimated the ratio of cancer and teratoma, or the relative probability of cancer. The use of these two models supports the clinical notion that the probability of necrosis is of predominant importance for the decision to resect a residual mass and that the ratio of cancer and teratoma is a second consideration. 3 The probability of necrosis and the relative probability of cancer were related to factors known before resection (predictors). The odds ratio (OR) was used as the measure of association. Relationships between predictors and outcomes were first estimated univariately within each study. If a test for homogeneity indicated no major heterogeneity (P > .10) of the relationships, the data were pooled using the Mantel-Haenszel method (EGRET statistical package; Statistics and Epidemiology Research Corporation, Seattle, WA). Predictors have statistically significant effects (P < .05) if the 95% confidence interval (CI) of the OR does not include the value 1. Multivariate logistic regression analysis was used to estimate the probability of necrosis and the relative probability of cancer based on the combination of predictors. Because the aim of this analysis is prediction, all variables contributing information should be included in the models." Therefore, the multivariate analyses included all predictors with P less than .50 in the univariate analysis. Of the three variables related to mass size (prechemotherapy size, postchemotherapy size, and shrinkage), the postchemotherapy size and shrinkage were candidates for use in the multivariate models. Differences between the coefficients of the predictors between the studies were checked by adding interaction terms of the predictors and study number. That the relationships were constant in time was checked by adding interaction terms of the predictors and year of treatment.
Evaluation of Model Performance
Predictive accuracy of the multivariate models can be distinguished in reliability (or calibration) and discrimination. Reliability refers to the amount of agreement between predicted and observed outcomes. For instance, if patients with certain characteristics are predicted to have a 70% chance of necrosis at resection, then 70% of such patients should actually have necrosis at resection. A graphic impression of reliability was obtained by plotting observed frequencies of the outcome (necrosis/cancer) against predicted probabilities. Reliability was tested by the Hosmer-Lemeshow goodness-of-fit test25 (BMDP module LR; BMDP Statistical Software, Inc, Los Angeles, CA), which evaluates the correspondence between the predicted probabilities of a model and the observed frequencies over groups spanning the entire range of probabilities.
Discrimination was assessed using receiver operating characteristic (ROC) analysis. The ROC curve is a plot of the true-positive rate (sensitivity) versus the false-positive rate (1 -specificity) evaluated at consecutive cutoff points of the predicted probability. The area under the ROC curve forms a suitable number to summarize the discriminative ability of a predictive model. 26 .
2 7 For all possible pairs of patients, the area represents the proportion in which the patients with that outcome (necrosis/cancer) had a higher probability than the patients without the outcome. A useless predictive model, such as a coin flip, would yield an area of .5. When the area is 1.0, the model discriminates perfectly. For our prediction problem, a value greater than .6 may be interpreted as reasonable, greater than .7 as satisfactory, and greater than .8 as good with respect to discriminative ability. Validity of model performance was distinguished internally and thirds of all patients (66%, 62%, and 69%, respectively). evaluated on the full sample. In this way, the discriminative ability Half of the patients had a prechemotherapy mass size --of the models in future but similar patients is estimated. Moreover, 50 mm (55%), a postchemotherapy mass < 20 mm bootstrap estimates were used to derive the final predictive models by correcting the logistic regression coefficients for overoptimism.
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(52%), or a shrinkage in transversal direction during cheExternal validity refers to the validity of the results of this analysis motherapy > 50% (57%). A minority of the patients was when applied to patients in other centers. To assess external validity, treated before 1981 (11%). The histology at resection was each study was left out of the full sample once. The models were 45% necrosis, 42% mature teratoma, and 13% cancer. fit on the remaining studies. Discriminative power was tested on the The relative probability of cancer was 70 / (70 + 236) study not included in the fitting procedure (test sample).
or 23% on average. Study no. 5 contained patients with RESULTS larger masses compared with the other studies, with less Table 4 lists the distribution of patient characteristics shrinkage during chemotherapy, necrosis in 20% only of in each of the six study groups. Overall, half of the pathe patients and cancer in 35% of the patients. Abbreviation: rc, reference category. *The ORs were significantly heterogenous between the 6 studies (P = .016). tThe 95% CI could not be calculated because of empty cells in some studies. Table 5 lists the results of the univariate analyses. ORs higher prechemotherapy LDH level (Table 5 ; P = .020).
for necrosis were reasonably homogeneous between studThe OR of the primary tumor histology was significantly ies; all tests for homogeneity had P greater than .15. All heterogenous (P = .016). The OR was greater than one predictors had significant relationships with the finding in studies no. 1 to 4 and less than one in studies no. 5 of necrosis at resection. Patients with a teratoma-negative and 6. Therefore, the primary tumor histology cannot be primary tumor histology had necrosis at resection in 60% used to distinguish between cancer and teratoma. Precheof the cases compared with 32% in patients with teratomamotherapy AFP and HCG levels were excluded as prepositive primary tumor histology. The following prechedictors in the multivariate models (P > .50). Cancer was motherapy tumor marker levels were related to the finding found in only 4% (seven of 162) of the patients with of necrosis at resection: normal AFP, normal HCG, or residual masses < 10 mm and in 5% (eight of 155) of elevated LDH. Smaller prechemotherapy or postchemothe patients with a shrinkage >-70%. therapy masses contained necrosis more often, as well as
The multivariate model for necrosis included 544 pamasses that were reduced largely in size during chemotients, and 115 of 3,264 (3.5%) of the values were imputed therapy (large shrinkage). An increase in tumor size dur- (Table 6 ). All predictors for necrosis were significant (P ing chemotherapy precluded the finding of necrosis (zero < .003), as well as the multivariate model as a whole (P of 46 patients).
< .0001). Dichotomous characteristics (present/not presCancer could be distinguished from teratoma by a ent) that predict necrosis included a teratoma-negative primary tumor histology and normal prechemotherapy AFP and HCG levels. Three other predictors were used as continuous variables. The natural logarithm (In) appeared to be the optimal transformation of LDHs,. The square root of the residual mass size was taken. Shrinkage of the mass during chemotherapy was used as a continuous, untransformed variable, and the OR was calculated per 10% decrease. Thus, a decrease of 10% indicated an approximately 1.2-times-higher probability of necrosis compared with no decrease, simultaneously adjusting for the other predictors. The multivariate model for the relative probability of cancer included 299 patients (77 of 897, or 8.6% of values imputed). Prechemotherapy LDH level, postchemotherapy mass size, and shrinkage were used as predictors, resulting in a significant model (P = .003). The relationship of the predictors did not vary significantly with study or year of treatment in both multivariate models (P > .10).
Reliability of the multivariate models is shown in Fig  1. Overall, the correspondence between observed and expected probabilities is good. In patients with a predicted probability of necrosis greater than 80%, the observed probability was 66 of 77 (86%). The goodness-of-fit tests indicated no lack of fit of the models (necrosis, P = .59; cancer, P = .34). Discriminative ability of the multivariate models is shown in Fig 2. Clearly, discrimination of necrosis from another histology is much more feasible than discrimination of cancer from teratoma.
Validity of the models is listed in Table 7 . Assessment of internal validity indicates that overall discriminative ability of the model for necrosis is expected to be good in similar patients (area, .83). The models for cancer will have less discriminative ability (area, .65). The external validation procedure mimics the situation that one of the studies would not have been included in the analysis. Table 7 shows that the necrosis model discriminates well in all studies, with some higher discrimination in study no. 4 and some lower discrimination in study no. 6. The second model discriminates reasonably in studies no. 3, 5, and 6.
When the multivariate analysis is restricted to the pa- 
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tients with complete values only, the necrosis model remains very similar with respect to both the ORs and model performance. However, the model distinguishing between cancer and teratoma has a smaller OR for LDH in the complete case analysis (OR = 1.50 v OR = 1.70; Table 7 ), and its discriminative ability is inferior to the model with imputation of missing values (area -.60 v area ; .65).
Finally, the two multivariate models are presented in a prognostic score chart (Table 8 ). This score chart is intended to facilitate the estimation of the probabilities of necrosis, mature teratoma, and cancer at resection in clinical practice using the final models. Scores for each predictor were derived from the logistic regression coefficients, which were reduced by a correction for overoptimism (multiplied by .955 in the necrosis model and by .870 in the cancer model), and subsequently multiplied by 10 and rounded to whole numbers. Ten points on the score chart correspond to an OR of e t = 2.72; an OR of two (doubling of the odds) is obtained by a score of seven points. Values for continuous predictors are given with such intervals that the scores show small steps, but scores for intermediate values may be estimated by linear interpolation.
For individual patients, the scores corresponding to the values of the predictors can be filled in on the score chart. An individual sumscore consists of the sum of all scores and a constant that represents the score if all values were zero. Figure 3 shows the probabilities corresponding to this sumscore.
The use of the score chart is illustrated with two patients (Table 9 ). Patient no. 1 had a teratoma-negative primary tumor, normal AFP and HCG levels before chemotherapy, LDH level three times the normal level, and a residual mass of 10 mm, which measured 50 mm before chemotherapy (shrinkage, [50 -10] / 50; 80%). Patient no. 2 had a teratoma-positive primary tumor, an elevated AFP level, and other characteristics the same as patient no. 1. The sumscores for patient no. 1 are +30 and -12, and for patient no. 2 + 12 and -12 (necrosis and cancer, respectively). The corresponding probabilities can be read from Fig 3. Patient no. 1 has a 95% probability of necrosis, leaving approximately 5% for the sum of the probabilities of teratoma and cancer. His relative probability of cancer is approximately 25% (Fig 3) . This means that the absolute probability of cancer is approximately 25% -5% (1.25%), and complementarily, the probability of teratoma is approximately 3.75%. Alternatively, the exact probabilities can be calculated using the formulas under Table 8 : necrosis, 94.6%; teratoma, 4.1%; and cancer, 1.3%. The probabilities for patient no. 2 are 75.5%, 18.5%, and 6.0%, respectively.
DISCUSSION
We developed two models to predict the histology of residual retroperitoneal masses in patients who were treated with cisplatin-based chemotherapy for metastatic NSGCT and who obtained normal values of AFP and HCG levels before resection. The first model aimed to predict the finding of necrosis only, whereas the second model was developed to separate cancer from mature teratoma in patients without necrosis. Individual patient data from six study groups were available, providing the largest data set of this type of patients thus far. 3 -5,7-9, [13] [14] [15] 20, 21 The model for necrosis consisted of six predictors, that were highly significant when analyzed alone (univariately) or combined (multivariately). Predictors for necrosis were a teratoma-negative primary tumor, normal prechemotherapy AFP or HCG level, elevated prechemotherapy LDH level, a relatively small residual mass, and a large shrinkage of the mass during chemotherapy. The model distinguishing cancer from teratoma consisted of three predictors that together constituted a statistically significant multivariate model. Cancer was found relatively more often if prechemotherapy LDH level was elevated, the residual mass was larger, and if a large shrinkage of the mass occurred during chemotherapy.
Higher values of prechemotherapy LDH are thus found related with a higher probability of necrosis but also with a higher relative probability of cancer. This implies that the probability of mature teratoma decreases with higher prechemotherapy LDH values. The absolute probability of cancer is lowered by higher LDH values in most patients because the multivariate OR of LDH for cancer is smaller than for necrosis ( (1 + e-(s. core(cnceri/10)]; probability (teratoma), 1 -[probability(necrosis) + probability(cancer)]. Predicted probabilities corresponding to the sumscores as calculated with the prognostic score chart ( Table 8 ; see text). For example, a sumscore of +15 corresponds to a probability of 82%.
residual masses who respond to chemotherapy (as indicated by normalization of AFP/HCG levels) form a favorable subgroup of patients with a prechemotherapy high LDH level.
The two models were reliable in that the observed probabilities agreed with predicted probabilities. Internal and external validation procedures showed that necrosis could be discriminated well from other histologies, but that cancer could only reasonably be distinguished from teratoma. It should be realized that the probability of cancer strongly depends on the probability of necrosis, as estimated with the first model. For example, if the estimated probability of necrosis is very high, eg, 95%, the probability of cancer can never be higher than 5%. If we use the average relative probability of cancer (23%) instead of the second model, this results in a risk of cancer of only 23% * 5% (1.2%). Thus, even when no predictors for the ratio of cancer and mature teratoma are used, the risk of cancer will be very low once the probability of necrosis is high.
The observation that mature teratoma cannot be distinguished easily from cancer may be explained partly by the fact that the histologic distinction between cancer and mature teratoma is made less clearly than the distinction between purely benign tissue (necrosis/fibrosis) and other tissue. For example, one study' 9 described that the histologic classification changed in a substantial proportion of the patients when reviewed with the Indiana criteria 32 for the diagnosis of cancer. In five patients (12%), the diagnosis changed from cancer to atypia, and in three patients (7%), from other diagnoses to cancer.19 1184 The final models were presented in a prognostic score chart, the use of which was illustrated in two patients, both with residual masses of 10 mm. Taking into account all prognostic factors, the probability of necrosis was very high (95%) in the first patient, and somewhat lower (76%) in the second patient. The probabilities for cancer and teratoma were 1.3% and 4.1% for the first patient, and 6% and 18% for the second patient, respectively. Should both patients undergo laparotomy? Or more generally, can we define thresholds for the decision to resect a residual mass? Should resection not be performed if the probability of necrosis is greater than 80%, or is the threshold as high as 90%? And what should we accept as the risk of cancer?
These thresholds need to be determined by the balance between the expected benefits and risks of resection. The risks of resection include long-term morbidity caused by surgery, especially ejaculation problems, which depend on the size and location of the residual mass and the extent of surgery.6, 20 ,
33
-35 Short-term morbidity consists of the hospital stay and complications such as hemorrhage, renal failure, and lymphocele. 34 The mortality of laparotomy is low, presumably less than 1% in most experienced centers, but risk estimates for individual patients may be higher.
If mature teratoma or cancer is present in the residual mass, the patient is expected to benefit from resection. The prognosis then is generally favorable, with 5-year relapse-free survival greater than 85% after resection of mature teratoma, and 50% to 80% after resection of cancer. [6] [7] [8] 16, 19, [36] [37] [38] Resection of viable cancer cells is usually followed by two additional cycles of chemotherapy. It has been suggested that this postresection chemotherapy preferably should be a different regimen than that given before resection. 3 ' 7 Yet an expectant policy after complete resection of cancer has also been followed (Horwich A, personal communication, September 1992). If resection is not performed, masses that contain mature teratoma may start to grow during a follow-up of months or even years (growing teratoma syndrome). 39 Resection may then be more complicated than it would have been shortly after the end of chemotherapy. Although residual mature teratomas have a less abnormal karyotype than the primary tumor, a risk of malignant transformation has been reported. 40 "" Leaving masses with residual cancer unresected involves a serious risk. However, it is uncertain how many of the patients with histologically viable cancer cells will eventually relapse. It may be hypothesized that the risk of relapse also depends on the extensiveness of cancer cells in the residual mass, with a low probability of relapse if only small foci of malignancy remain. No data are currently available regarding this relationship. When relapse of malignancy occurs after leaving mature teratoma or cancer unresected, salvage chemotherapy is administered. However, these regimens have rather limited efficacy (approximately 2 5 %1,2,45,46), and late relapses frequently have a high degree of chemotherapy resistance. Given these uncertainties with the benefits of resection, it is difficult to indicate thresholds for the probability of necrosis and cancer. These thresholds also may depend on country-or center-specific circumstances such as the
